Drug profile · INN
pegunigalsidase alfa-iwxj
ELFABRIO
pegunigalsidase alfa-iwxj (ELFABRIO) is a globotriosylceramide hydrolytic enzyme. Route of administration: single-use. Current US regulatory status: approved.
Drug details — pegunigalsidase alfa-iwxj
- US status
- approved
- Class
- —
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
pegunigalsidase alfa-iwxj (ELFABRIO) is a globotriosylceramide hydrolytic enzyme. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Globotriosylceramide hydrolytic enzyme
Primary target: Globotriosylceramide
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegunigalsidase alfa-iwxj?
pegunigalsidase alfa-iwxj (ELFABRIO) is a globotriosylceramide hydrolytic enzyme. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for pegunigalsidase alfa-iwxj?
ELFABRIO is a marketed brand name for pegunigalsidase alfa-iwxj. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegunigalsidase alfa-iwxj?
pegunigalsidase alfa-iwxj has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.